PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
96.69%
Cash & equivalents growing 96.69% while TRAW's declined -43.42%. Peter Lynch would see this as a sign of superior liquidity management.
No Data
No Data available this quarter, please select a different quarter.
96.69%
Below half of TRAW's -43.42%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
119.86%
Other current assets growth < half of TRAW's -10.78%. David Dodd sees a leaner approach to short-term items.
94.31%
Below half of TRAW's -24.67%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-6.34%
Both TRAW and the company show zero PP&E (Net) Growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-4.92%
Both TRAW and the company show zero Total Non-Current Assets Growth.
No Data
No Data available this quarter, please select a different quarter.
78.33%
Below half of TRAW's -24.35%. Michael Burry sees a potential red flag for stagnation or capital shortage.
-11.61%
Less than half of TRAW's 9.60%. David Dodd sees a more disciplined AP approach or lower volume.
-42.55%
Higher Short-Term Debt Growth compared to TRAW's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
11.61%
Higher Deferred Revenue (Current) Growth compared to TRAW's zero value, indicating better performance.
No Data
No Data available this quarter, please select a different quarter.
-11.56%
Less than half of TRAW's 4.01%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-9.36%
Above 1.5x TRAW's -1.97%. Michael Burry sees a strong spike vs. competitor. Check coverage and debt ratios.
No Data
No Data available this quarter, please select a different quarter.
-11.23%
Less than half of TRAW's 1.93%. David Dodd sees far fewer liability expansions relative to competitor.
36.01%
Above 1.5x TRAW's 1.69%. Michael Burry suspects heavy new equity expansion or dilution.
-2.61%
≥ 1.5x TRAW's -0.91%. David Dodd sees higher yoy retained profits than competitor.
-6.95%
Less than half of TRAW's 22.22%. David Dodd sees fewer intangible or market-driven swings than competitor.
No Data
No Data available this quarter, please select a different quarter.
193.87%
Below half TRAW's -195.96%. Michael Burry sees potential underperformance in building shareholder capital.
78.33%
Below half TRAW's -24.35%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
-9.95%
Higher Total Debt Growth compared to TRAW's zero value, indicating worse performance.
-116.79%
Less than half of TRAW's 43.42%. David Dodd sees better deleveraging or stronger cash buildup than competitor.